NCT07145411

HPC Offered for PRESERVE Expansion

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 10 (estimated)
• Sponsor: Ossium Health, Inc. · Industry
• Sex: All
• Age: 12 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product

Conditions

• Bone Marrow Transplant (BMT)

Interventions

Type	Name	Description
OTHER	Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)	The HOPE Program does not include any investigational drugs. The medicines and procedures in this program are standard of care for a transplant. Bone marrow cells from a deceased organ and tissue donor for use in your transplant is the only product offered to you by Ossium Health.

Timeline

• Start date: 2024-06-27
• Primary completion: 2027-08-01
• Completion: 2029-08-01
• First posted: 2025-08-28
• Last updated: 2025-08-28

Locations

4 sites across 1 country: United States